Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

API Import to Russia (October 2020)

Thursday, December 10, 2020

Between January and October 2020, Russia imported RUB 134.1 bln worth of APIs (customs clearance and VAT included), which is in monetary terms (rubles) 20% higher than in 2019. The import volume in physical terms (tons) amounted to 12.1 thousand tons, with the growth rate of +12%.

The importers’ activity in October 2020 did not have any significant effect on the growth rates for the period between January and October. The growth rates were only +5.6% in monetary terms and -4% in physical. However, even those growth rates do not look that bad against the August results (-27% and -24% in monetary and physical terms, respectively).

Dolutegravir Sodium was the most imported API in monetary terms in October 2020. The import volume amounted to RUB 1.6 bln. The company GSK was importing it from Japan for the production of Tivicay at the facilities of Servier Rus at the so-called New Moscow. Pneumococcal Polysaccharide Conjugates, imported by Petrovax, comes second. Petrovax is a local partner of Pfizer in the production of the ready-made form of Prevenar.

Paracetamol and Acetylsalicylic Acid were the most imported APIs in physical terms (283.5 and 165.1 tons, respectively). The import of Paracetamol has increased by 2.2 times, while that of Acetylsalicylic Acid has dropped by 4.5%. However, those are the growth rates of October 2020; the growth rates for the period between January and October 2020 are +54% and +26%, respectively. In October 2020, Paracetamol was imported by six companies, and Acetylsalicylic Acid by five, although Pharmstandard accounts for the largest import volumes in both cases.

Among the APIs imported in October 2020, Guaifenesin was the only one that had not been imported before (Biocom imported 25 kg for RUB 100,000). As for the period between January and October 2020, the number of the “new” APIs are as many as 79, among which commercial API Favipiravir accounted for the largest import volume. Russia started importing Favipiravir in April 2020, and the volume has since then reached RUB 1.2 bln and 4.4 tons, 90% of which has been imported from China, the rest from India. The API has been imported by 4 companies, with Drug Technology (R-Pharm group) accounting for 70% of the import.

Growth rates of pharmacopoeial and commercial API import to Russia (EEU countries excluded), free circulation prices including customs clearance and VAT (2016 – 2019, January – October 2020)